News

Hubble Therapeutics Secures Series A Funding for Gene Therapy

Hubble Therapeutics Secures Series A Funding for Gene Therapy

Hubble Therapeutics Closes Series A Funding Round

Hubble Therapeutics LLC, a pioneering biotechnology company dedicated to combating pediatric blindness, has made headlines with the successful closing of a $7.3 million Series A funding round. This significant boost will enable the company to advance its lead gene therapy candidate, HUB-101, towards crucial human clinical trials, marking a major step in their mission to develop effective treatments for children facing severe vision loss.

Understanding the Impact of LCA16 and SVD

The gene therapy Hub-101 specifically targets two extremely rare and debilitating eye disorders: Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). These conditions are linked to mutations in the KCNJ13 gene, an essential component for the function of ion channels found in the retina’s pigment epithelium. Affected children often exhibit symptoms before the age of five, which lead to gradual retinal degeneration and ultimately, blindness.

Expert Insights on Gene Therapy Development

Dr. Bikash Pattnaik, an esteemed professor at the University of Wisconsin-Madison and a scientific co-founder of Hubble Therapeutics, spoke passionately about the advancements in curative gene therapies for inherited blindness. "The HUB-101 gene therapy for LCA16 not only represents a scientific breakthrough but also promises hope for families devastated by hereditary vision loss. Our goal is to push the boundaries of current therapeutic methods, offering innovative solutions for genetic diseases at their roots," he shared.

Partnerships to Propel Development Forward

To ensure the success of the HUB-101 program, Hubble Therapeutics has established partnerships with Andelyn Biosciences and Virscio. These collaborations are aimed at aiding in the development and manufacturing processes, as well as conducting essential IND-enabling studies to ensure the therapy's safety and efficacy. With these partnerships, Hubble Therapeutics is gearing up to enter the clinic in 2026, where they anticipate beginning Phase I/II clinical trials.

The Importance of Investment in Medical Research

Greg Keenan, Senior Director of WARF Ventures & Accelerator, expressed optimism regarding the research conducted at Hubble Therapeutics. "Our investment as the co-lead investor in this Series A round underscores our commitment to supporting innovative research aimed at altering the course of rare diseases. The collaboration between Hubble Therapeutics and Dr. Pattnaik epitomizes the transformative power of academic-industry joint efforts, and we're excited to witness the progress this research will bring," he stated.

Commitment to Patient-Centric Approaches

Jeff Sabados, the Founder and President of Hubble Therapeutics, emphasized the importance of their partnerships and investor relationships. He acknowledged the dedication of scientists, industry experts, and patient families, stating, "With our newly secured funding and robust partnerships, we are determined to enhance HUB-101's manufacturing capabilities and drive the necessary studies that will take us to the clinic. Our unwavering promise is to support families impacted by LCA16 and SVD and work towards restoring vision for affected individuals."

About Hubble Therapeutics

Hubble Therapeutics LLC, often referred to as HubbleTx, is firmly committed to its mission of developing gene therapies with a focus on pediatric eye diseases. Utilizing pioneering research from Professor Bikash Pattnaik’s lab at the University of Wisconsin-Madison, the company aims to address the genetic mutations causing severe vision loss in conditions like LCA16 and SVD. Their dedication to rigorous clinical development ensures that the therapies they offer are not only effective but also accessible to those in need. By fostering collaboration and innovation, HubbleTx strives to illuminate a hopeful path forward for patients battling these life-altering conditions.

Frequently Asked Questions

What is HUB-101?

HUB-101 is a gene therapy designed to treat Leber Congenital Amaurosis Type 16 and Snowflake Vitreoretinal Degeneration, two severe eye disorders affecting children.

How much funding did Hubble Therapeutics secure?

Hubble Therapeutics successfully closed a $7.3 million Series A funding round to advance their research and clinical trials.

Who is leading the research for HUB-101?

The research for HUB-101 is led by Dr. Bikash Pattnaik at the University of Wisconsin-Madison, who has a vast experience in developing gene therapies for pediatric blindness.

When does Hubble Therapeutics plan to start clinical trials?

Hubble Therapeutics expects to begin Phase I/II clinical trials for HUB-101 in 2026.

What is the goal of Hubble Therapeutics?

The primary goal of Hubble Therapeutics is to develop innovative gene therapies that restore vision in patients suffering from genetic eye diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 207

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 83

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 62

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 296

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 188

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Intuitive Machines Secures Major NASA Contract Worth $4.8 Billion

Updated Category News Views 85

Intuitive Machines Secures $4.8 Billion NASA Contract In the ever-changing landscape of space exploration, Intuitive Machines has recently landed a major contract from NASA worth up to $4.82 billion. This agreement aims to improve communication and navigation services for various near-space operations. Stock Prices Soar Following this announcement, Intuitive Machines saw...

Continue Reading
Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025

Updated Category News Views 399

Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025 The rapidly growing Cilantro Taco Grill has exciting plans to expand its footprint beyond the Chicagoland area in 2025, marking a pivotal moment in its journey. They are set to open their doors in new states, a development that signifies their success and commitment to delivering authentic Mexican flavors....

Continue Reading
Nightingale Ice Cream Sandwiches Launch Nationwide at Target

Updated Category News Views 242

Nightingale Ice Cream Sandwiches Launches in Target Stores Fans of ice cream sandwiches are in for a delightful treat as Nightingale Ice Cream Sandwiches is making its debut in select Target stores across the nation. This new venture brings signature chef-crafted flavors to shoppers, offering a taste of joy that has captured hearts and appetites. Your New Favorite Ice...

Continue Reading
Bybit Enhances User Experience with API for Flexible Savings

Updated Category News Views 180

Bybit Enhances User Experience with API for Flexible Savings Bybit, the world's second-largest cryptocurrency exchange by trading volume, has recently made a significant advancement by introducing API access for its On-Chain Earn and Flexible Savings products. This move aims to empower institutional users and developers to seamlessly connect with Bybit's infrastructure,...

Continue Reading
Empowering Indiana's Youth: The Impact of $30 Million Grant

Updated Category News Views 168

Transformative $30 Million Grant Boosts Youth Programs in Indiana An incredible investment from Lilly Endowment Inc. has led to remarkable growth and enhancement of programs across Indiana for Boys & Girls Club organizations. With a significant $30 million grant dedicated to expanding resources, mentorship, and safe spaces, clubs have been empowered to serve more young...

Continue Reading